At 52 weeks, orforglipron showed superior weight-loss maintenance vs placebo , with minimal regain in patients switching from semaglutide (regained 0.9 kg) and tirzepatide (regained 5.0 kg, which is still better than the placebo group)
No single data point should drive a strategic decision
While Medicare and Medicaid will start covering these drugs this summer, many patients on private insurance can't afford a once-a-week shot
Ask whether you should anticipate stopping any other medications, how to handle side effects like diarrhea, and what signs might suggest that the medication dosage needs adjustment
FancyMeds works with state-licensed compounding pharmacies that prepare prescriptions in accordance with applicable federal and state requirements
The follow-up periods in these trials typically ranged from 1.5 to 5 years, providing medium-term safety data